This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Refractory angina (RA) is a chronic condition characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronaryarterydisease (CAD).
Results from the open label roll-in cohort of patients having chronic myocardial ischemia with refractory angina showed an average increase in exercise tolerance of 107 seconds and an average of 82% reduction in angina episodes at the primary six-month follow-up endpoint compared to before receiving the study treatment.
Introduction Current guideline recommend functional imaging for myocardial ischaemia if coronary CT angiography (CTA) has shown coronaryarterydisease (CAD) of uncertain functional significance. However, diagnostic accuracy of selective myocardial perfusion imaging after coronary CTA is currently unclear.
Objectives There are few reports regarding the prognosis in patients with obstructive coronaryarterydisease (OCAD) and vasospastic angina (VSA). This study investigated the clinical characteristics and clinical outcomes in patients with VSA and OCAD, especially regarding provoked spasm phenotypes and sites.
The favorable efficacy of CHM was primarily presented on five main conditions, coronaryarterydisease, hypertension, heart failure, restenosis, and angina pectoris. CHM, with or without conventional treatment, showed a consistent beneficial effect in various cardiovascular diseases.
Background:The impact of antianginal therapies on the health status of coronaryarterydisease (CAD) patients who have undergone coronary revascularization has not been extensively researched. Methods:We analyzed data from 1,556 patients enrolled in the GREAT Disease Registry Study (Clinicaltrial No.
Background Cardiac 15O-water PET is a noninvasive method to evaluate epicardial and microvascular dysfunction and further quantitate absolute myocardial blood flow (MBF).
Methods We retrospectively enrolled 237 patients who underwent elective coronary angiography (CAG) for stable angina or positive stress test results >1 year after CABG. Uric acid to albumin ratio (UAR) is a new marker which associated with cardiovascular mortality. We aim to evaluate the relationship between the SVGD and UAR.
It was compared with N-terminal pro–B-type natriuretic peptide (NT-proBNP), peak troponin T-us value GRACE (Global Registry of Acute Coronary Events), CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology and American Heart Association guidelines (..)
Takotsubo is a sudden event, not one with crescendo angina. Hospital Course The patient was taken emergently to the cath lab which did not reveal any significant coronaryarterydisease, but she was noted to have reduced EF consistent with Takotsubo cardiomyopathy. Learning Points: 1. Lindahl et al. References: 1.
In the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial, researchers examined the risk of ischemic events in patients with stable coronaryarterydisease. years, with 57.1% occurring within 30 days after CABG. Original article: Redfors B et al.
The optimal surveillance strategy after percutaneous coronary intervention (PCI) for high-risk patients with multivessel or left main coronaryarterydisease (CAD) remains uncertain. The primary outcome was a composite of death from any cause, myocardial infarction, or hospitalization for unstable angina at 2 years.
Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform. Use Heart to Act on Angina.
This new study found that among a sample of more than 3,100 people with heart disease, 89% consumed more than the recommended daily maximum of 1,500 mg of sodium and, on average, study participants consumed more than twice this amount.
Subscribe now Stenting stable coronaryarterydisease has not been convincingly proven to reduce the risk of future heart attacks or death 1. Whether stenting a narrowed coronaryartery improves symptoms such as chest pain (angina) or shortness of breath is a very different question. What About Symptoms?
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronaryarterydisease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Differences in QoL (measured using the EuroQol Research Foundation instrument) and HRU between patients in rural and urban settings were evaluated in this post hoc analysis. Data were collected at baseline and every 6 months for 24 months. to 1.00, p=0.04); ERR=0.84 (95% CI, 0.78 to 0.92, p<0.001); ERR=0.86 (95% CI, 0.81
The primary endpoint consisted of a composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5). in the medical therapy group.
In a study published by the American Heart Association, “Sex and Age Differences in the Association of Depression With Obstructive CoronaryArteryDisease and Adverse Cardiovascular Events,” researchers investigated 3,237 patients (35% women) undergoing coronary angiography to evaluate for coronaryarterydisease (CAD).
One of the most effective treatments for severe coronaryarterydisease, a type of cardiovascular disease, is coronaryartery bypass grafting (CABG), a procedure designed to restore blood flow to the heart. But does coronaryartery bypass surgery also improve erectile capacity?
vs. 6.4%), and Black patients were more likely to be readmitted for angina (34.0 5.03] was associated with an increased risk of readmission for angina, while female sex was associated with decreased odds of repeat angiography (OR, 0.36; 95% CI, 0.14–0.90) Men were significantly more likely to have repeat angiography (13.7 vs. 19.1%).
The highly impactful International Study of Comparative Health Effectiveness With Medical and Invasive Approaches ( ISCHEMIA ) trial investigated the effectiveness of invasive (INV) versus conservative (CON) strategies for managing stable coronaryarterydisease. Original article: Gaudino M et al. EuroIntervention.
PurposeThe study aimed to assess various characteristics of coronary computed tomography angiography (CCTA) in patients presenting with suspected coronaryarterydisease (CAD). Patients underwent CCTA for 0.56 months (median 3.3 months) before the SAP and ACS event.
Personalized Cardiometabolic Care TRANSFORM Program for CoronaryArteryDisease (CAD) : The TRANSFORM program focuses on atherosclerosis-based care strategies rather than traditional risk-based approaches. The trial highlights the importance of reevaluating and optimizing thrombolytic therapies for better patient outcomes.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content